We are live on ! Find out more
ONTXW

Onconova Therapeutics, Inc. Warrants

Delisted

ONTXW was delisted on the 23rd of July, 2021.

4 hedge funds and large institutions have $15K invested in Onconova Therapeutics, Inc. Warrants in 2018 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

43% less funds holding

Funds holding: 74 (-3)

98% less capital invested

Capital invested by funds: $611K → $15K (-$596K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 3

Holders
4
Holders Change
-3
Holders Change %
-42.86%
% of All Funds
0.09%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
Increased
1
Reduced
Closed
3
Calls
Puts
Net Calls
Net Calls Change

ONTXW Hedge Fund Activity: Q2 2018 in Review

4 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Onconova Therapeutics, Inc. Warrants (ONTXW) for Q2 2018, worth a combined $15K — down 98% from $611K a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of ONTXW and 0 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 1 added.

The largest buyer was UBS Group, adding an estimated $280. The largest seller was 683 Capital Management, exiting entirely with an estimated $172K sold.

  • 4 institutional investors held Onconova Therapeutics, Inc. Warrants (ONTXW) as of Q2 2018, down from 7 in Q1 2018.
  • Funds reported $15K of Onconova Therapeutics, Inc. Warrants stock for Q2 2018, down 98% quarter-over-quarter.
  • 0 funds opened new Onconova Therapeutics, Inc. Warrants positions in Q2 2018 and 3 closed out, a net change of -3 holders.
  • The largest Onconova Therapeutics, Inc. Warrants buyer in Q2 2018 was UBS Group, an estimated $280 added.
  • The largest Onconova Therapeutics, Inc. Warrants seller in Q2 2018 was 683 Capital Management, an estimated $172K sold.

Based on aggregated 13F filings for Q2 2018.